Login to Your Account

Financings Roundup

TxCell Lands $16M to Advance Immunotherapy for Crohn's

By Cormac Sheridan
Staff Writer

Tuesday, November 27, 2012
Continuing Europe's recent push in cell therapy development, TxCell SA raised €12.4 million (US$16.1 million) in a Series C round to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription